SEC Tracker
Get the app

NeuroPace NPCE

NeuroPace Q3 FY23: revenue $16.4M; diluted EPS −$0.28

Form
10-Q
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers NeuroPace reported for Q3 FY23, the quarter ended Sep 30, 2023, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$16.4MNo year-earlier figure tagged10-Q income statement, on EDGAR
  2. Net income−$7.3MNo year-earlier figure tagged10-Q income statement, on EDGAR
  3. Diluted EPS−$0.28No year-earlier figure tagged10-Q income statement, on EDGAR
  4. Cash and cash equivalents$9.7MNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
  5. Cash from operations−$2.3MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when NeuroPace files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 3841 and related industry codes: the same peer list as the financial tables.

  1. ClearPoint Neuro CLPT public float $328M, Jun 30, 2025
  2. Outset Medical OM public float $335M, Jun 30, 2025
  3. SS Innovations International SSII public float $270M, Jun 30, 2025
  4. EBR Systems EBRCZ public float $351M, Jun 30, 2025
  5. Treace Medical Concepts TMCI public float $266M, Jun 30, 2025